FDA approved 53 novel drugs in 2020

6 January 2021
fda_big

Despite dealing with the urgent need to evaluate vaccines, drugs and diagnostics tests relating to the COVID-19 pandemic, the US Food and Drug Administration cleared a bumper number of novel drugs last year.

The FDA approved a total of 53 new products in 2020, the second-highest number in more than 20 years, and well above the 48 new meds cleared in 2019.

Among the notable approvals were two treatments for Ebola virus, the first fully-approved antiviral for COVID-19, the first oral treatment for spinal muscular atrophy, and the first treatment for children with a rare genetic disease that causes them to develop tumors on their nerves. The year also brought 10 new cancer treatments, including another two antibody-drug conjugates, a class that has become an increasingly permanent fixture in the new drug list.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical